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Abstract
N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) and ketamine can evoke
psychotic symptoms in normal individuals and schizophrenic patients. Here, we have examined the
eﬀects of PCP (5 mg/kg) and ketamine (25 mg/kg) on the eﬄux of serotonin (5-HT) in the medial pre-
frontal cortex (mPFC) and their possible blockade by the antipsychotics, clozapine, olanzapine and halo-
peridol, as well as ritanserin (5-HT2A/2C receptor antagonist) and prazosin (a1-adrenoceptor antagonist).
The systemic administration, but not the local perfusion, of the two NMDA receptor antagonists markedly
increased the eﬄux of 5-HT in the mPFC. The atypical antipsychotics clozapine (1 mg/kg) and olanzapine
(1 mg/kg), and prazosin (0.3 mg/kg), but not the classical antipsychotic haloperidol (1 mg/kg), reversed
the PCP- and ketamine-induced increase in 5-HT eﬄux. Ritanserin (5 mg/kg) was able to reverse only
the eﬀect of PCP. These ﬁndings indicate that an increased serotonergic transmission in the mPFC
is a functional consequence of NMDA receptor hypofunction and this eﬀect is blocked by atypical
antipsychotic drugs.
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Introduction
The hypothesis of the N-methyl-D-aspartate (NMDA)
receptor hypofunction in schizophrenia stems from
the observation that NMDA receptor antagonists such
as phencyclidine (PCP) and ketamine can evoke psy-
chotic symptoms in normal individuals and aggravate
them in schizophrenic patients (for review, see Krystal
et al., 2003). For these reasons, NMDA receptor
antagonists have been used in experimental animals to
model neurochemical and behavioural changes that
occur in schizophrenia. Thus, systemic administration
of PCP or dizocilpine (MK-801) increases the ﬁring
of neurons of the medial prefrontal cortex (mPFC) and
causes hyperlocomotion and stereotypies ( Jackson
et al., 2004 ; Jodo et al., 2003 ; Suzuki et al., 2002).
However, microiontophoretically applied PCP does
not alter either mPFC cell ﬁring or hyperlocomotion
(Suzuki et al., 2002), which suggests that the NMDA
receptor antagonists turn on mPFC neurons through
the stimulation of excitatory inputs from brain areas
outside the mPFC. NMDA receptor antagonists
have also been shown to increase extracellular glu-
tamate (Abekawa et al., 2003 ; Lorrain et al., 2003 ;
Moghaddam et al., 1997), dopamine (Adams and
Moghaddam, 1998; Mathe´ et al., 1999 ; Schmidt
and Fadayel, 1996), and serotonin (5-HT) (Adams and
Moghaddam, 2001; Martin et al., 1998a; Millan et al.,
1999) in the mPFC. The source of this glutamate is
presently unknown, but it has been proposed that
NMDA receptor antagonists may block a tonic inhibi-
tory inﬂuence of c-aminobutyric acid (GABA) neurons
over an excitatory projection to the mPFC ( Jodo et al.,
2005 ; Krystal et al., 2003 ; Lorrain et al., 2003 ;
Moghaddam et al., 1997). The increases in dopamine
and 5-HT release are probably due to increments in
dopaminergic (Pawlowski et al., 1990 ; Schmidt and
Fadayel, 1996) and serotonergic (Lejeune et al., 1994)
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cell ﬁring in the ventral tegmental area and the dorsal
raphe nucleus respectively. This latter activation could
result from an enhanced glutamatergic output from the
mPFC neurons, including those projecting to the dorsal
raphe nucleus. Indeed, the electrical or pharmacologi-
cal stimulation of the mPFC increases serotonergic
transmission in the dorsal raphe nucleus (Celada et al.,
2001 ; Martı´n-Ruiz et al., 2001). Nevertheless, a local
eﬀect of NMDA receptor antagonists in the dorsal
raphe nucleus cannot be ruled out (Callado et al., 2000).
Although a hyperactive serotonergic transmission
in the mPFC has been implicated in schizophrenia
(Meltzer, 1989) and in the hyperlocomotion induced
by a reduced NMDA receptor function (Miyamoto
et al., 2001), the precise role of cortical 5-HT on these
eﬀects remains to be determined. However, a relation-
ship between 5-HT and schizophrenia stems from two
main observations. First, 5-HT2A/2C receptor agonists
elicit hallucinogenic states in humans resembling
those present in positive symptomatology (Gouzoulis-
Mayfrank et al., 1998), and markedly increase the
ﬁring rate of pyramidal neurons in the mPFC (Puig
et al., 2003). Likewise, the selective activation of 5-
HT2A receptors in rodent mPFC increases local 5-HT
release (Amargo´s-Bosch et al., 2004 ; Bortolozzi et al.,
2003 ; Martı´n-Ruiz et al., 2001 ; Puig et al., 2003), which
could point to an activation of mPFC serotonergic
transmission in the illness. Second, atypical anti-
psychotics are eﬀective 5-HT2A receptor antagonists.
In previous studies we have shown that antipsychotic
drugs reverse the increase of the local extracellular
5-HT induced by the pharmacological stimulation of
the mPFC with 5-HT2A and a1-adrenergic receptor
agonists (Amargo´s-Bosch et al., 2003 ; Bortolozzi et al.,
2003). In the present work, we have examined the
eﬀects of clozapine, olanzapine and haloperidol on
the eﬄux of 5-HT in the mPFC elicited by PCP and
ketamine. In an attempt to understand the contri-
bution of 5-HT2A/2C and a1-adrenergic receptors in
the action of these antipsychotic drugs, the eﬀects of
ritanserin and prazosin were also tested.
Materials and methods
Animals
Male Wistar rats (Iﬀa-Credo, Lyon, France) weighing
250–280 g were used. They were maintained on a 12-h
light/dark cycle (lights on at 07:00 hours) and housed
three per cage before surgery and individually after
surgery. Food and water were always freely available.
All experimental procedures were carried out in strict
accordance with European Communities Council
Directive on ‘Protection of Animals Used in Experi-
mental and Other Scientiﬁc Purposes’ of 24 November
1986 (86/609/EEC) and were approved by the In-
stitutional Animal Care and Use Committees.
Drugs
Phencyclidine hydrochloride, ritanserin and prazosin
hydrochloride were purchased from Sigma-Aldrich
(Tres Cantos, Spain). Ketamine hydrochloride
(Ketolar1, 50 mg/ml) and haloperidol were pur-
chased as injectable solutions from Pﬁzer and Lab-
oratorios Esteve (Barcelona, Spain) respectively.
Clozapine was obtained from Tocris (Bristol, UK).
Olanzapine and citalopram hydrobromide were gen-
erously donated by Eli Lilly & Co (Indianapolis, IN,
USA) and H. Lundbeck A/S (Copenhagen-Valby,
Denmark) respectively. PCP and Ketolar1 were dis-
solved in distilled water or artiﬁcial cerebrospinal
ﬂuid according to the route of administration. Cloza-
pine, olanzapine, prazosin and ritanserin were dis-
solved in a few drops of glacial acetic acid and further
diluted with distilled water for systemic adminis-
tration, or artiﬁcial cerebrospinal ﬂuid (see below for
composition) for local application through dialysis
probes. When needed, the pH of the ﬁnal concen-
trations was adjusted to 6.5–7.0 with NaHCO3. Because
PCP and ketamine were administered intraperiton-
eally (i.p.) and subcutaneously (s.c.) respectively, two
diﬀerent control groups were run in parallel. One
group consisted of a ﬁrst s.c. injection followed 20 min
later by an i.p. injection of saline and served as control
for the experiment with PCP. The other group con-
sisted of two s.c. injections of saline and served as
control for the ketamine experiment. When anti-
psychotics, prazosin and ritanserin were administered
alone, a single s.c. injection of saline served as control
group.
Microdialysis procedures
Concentric dialysis probes with a 4-mm long mem-
brane were implanted under sodium pentobarbital
anaesthesia (60 mg/kg i.p.) in the mPFC (AP
+3.2 mm, L x0.8 mm, DV x6.0 mm; from Bregma)
according to Paxinos andWatson (1986). Microdialysis
experiments were conducted 20–24 h after surgery in
freely moving rats by continuously perfusing probes
with artiﬁcial cerebrospinal ﬂuid containing 125 mM
NaCl, 2.5 mM KCl, 1.26 mM CaCl2, 1.18 mM MgCl2 and
1 mM citalopram, at a rate of 1.5 ml/min. Dialysate
samples of 30 ml were collected every 20 min. After a
100-min stabilization period, four dialysate samples
were collected to obtain basal 5-HT values before
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pharmacological treatment. At the completion of
dialysis experiments, rats were given an overdose of
sodium pentobarbital and a Fast Green solution was
perfused through the dialysis probes to stain the
surrounding tissue.
Biochemical determinations
The concentration of 5-HT in dialysate samples
was determined by HPLC using a 3-mm octadecylsilica
(ODS) column (7.5 cmr0.46 cm; Beckman, San
Ramon, CA, USA) and detected amperometrically
with a Hewlett-Packard 1049 detector (Palo Alto, CA,
USA) set at an oxidation potential of 0.6 V. The
detection limit for 5-HT was estimated to bey1 fmol/
sample.
Experimental design
Basically, each experimental group started with the
collection of four dialysate samples before drug ad-
ministration (basal values). Then, a systemic injection
(i.p. or s.c.) of saline or a drug (clozapine, olanzapine,
haloperidol, prazosin or ritanserin), followed by the
administration of a NMDA receptor antagonist (PCP
or ketamine) or saline. To examine the local eﬀects of
NMDA receptor antagonists on extracellular 5-HT,
successive increasing concentrations of PCP or keta-
mine were perfused for 80 min following the collection
of four basal dialysate samples. The rats of the corre-
sponding control group were perfused only with arti-
ﬁcial cerebrospinal ﬂuid.
Statistics
Data (mean¡S.E.M.) are expressed as fmol/fraction
(uncorrected for recovery) and shown in ﬁgures
as percentages of basal values, averaged from four
fractions collected before treatment. The changes in
dialysate 5-HT were analysed by two-way repeated-
measures analysis of variance (ANOVA) with time
and drug as factors. Area under the curve (AUC) was
also calculated for the diﬀerent treatments and ex-
pressed as percentage from the same period of control
rats. When signiﬁcant eﬀects were found, post-hoc
Newman–Keuls tests were used to compare the eﬀects
of each drug (or combination thereof) with the corre-
sponding control group. The level of signiﬁcance was
set at p<0.05. For the sake of clarity, signiﬁcant eﬀects
are depicted only in the AUC ﬁgures.
Results
The basal (pre-drug) concentration of 5-HT was not
signiﬁcantly diﬀerent among all experimental groups
and amounted to 37.6¡1.7 fmol/sample (n=126). The
perfusion of PCP (10, 30, 100, 300 mM) or ketamine (100,
300, 1000 mM) in the mPFC did not change the local
concentration of 5-HT (Figure 1). There was no diﬀer-
ence between the three control groups used with
regard to dialysate 5-HT. As described thoroughly in
the literature, the systemic administration of PCP
(5 mg/kg i.p.) and ketamine (25 mg/kg s.c.) to rats
evoked a marked hyperlocomotion and stereotypies
(behavioural observation). The concentration of 5-HT
was also elevated signiﬁcantly following the systemic
administration of PCP (F1,12=17.28, p<0.002) and
ketamine (F1,12=16.26, p<0.002). The eﬀect of PCPwas
y20% higher than that of ketamine, but this diﬀerence
did not reach statistical signiﬁcance. The PCP-induced
increase of 5-HT was suppressed by clozapine 1.0 mg/
kg s.c. (F1,11=10.79, p<0.01), olanzapine 1.0 mg/kg s.c.
(F1,14=5.24, p<0.05), ritanserin 5.0 mg/kg i.p. (F1,11=
5.12, p<0.05) and prazosin 0.3 mg/kg s.c. (F1,9=14.08,
p<0.005), but not by haloperidol 0.1 mg/kg and
1.0 mg/kg s.c. (Figure 2). In a similar way, the keta-
mine-induced increase of 5-HT was abolished by
clozapine 1.0 mg/kg s.c. (F1,12=12.92, p<0.005), olan-
zapine 1.0 mg/kg s.c. (F1,14=5.61, p<0.05) and prazo-
sin 0.3 mg/kg s.c. (F1,12=30.66, p<0.0002), but not by
haloperidol 1.0 mg/kg s.c. and ritanserin 5.0 mg/kg
i.p. (Figure 3). When injected alone (Figure 4), cloza-
pine 1.0 mg/kg s.c. (F1,9=8.38, p<0.02), haloperidol
1.0 mg/kg s.c. (F1,7=6.39, p<0.05) and prazosin
0.3 mg/kg s.c. (F1,8=15.67, p<0.005), reduced mPFC
5-HT to the same extent (y70% of baseline values). In
contrast, ritanserin 5.0 mg/kg i.p. resulted in a 20%
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Figure 1. Eﬀects of the local perfusion of diﬀerent
concentrations (in mM) of PCP (n=5 for each concentration)
and ketamine (n=5 for each concentration) on the 5-HT eﬄux
in the mPFC. There was no signiﬁcant eﬀect of any NMDA
receptor antagonist at the concentrations tested. Data
(mean¡S.E.M.) are expressed as percentage of baseline.
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increase (F1,11=10.05, p<0.01) and olanzapine 1.0 mg/
kg s.c. produced no change in dialysate 5-HT. It was
of note that none of these drugs evoked any gross
behavioural change when administered alone (behav-
ioural observation).
Discussion
The ﬁrst main ﬁnding of this study is that the systemic
administration of the NMDA receptor antagonists,
PCP and ketamine, increases the eﬄux of 5-HT in the
mPFC. To the best of our knowledge, this was pre-
viously shown for PCP (Adams and Moghaddam,
2001; Martin et al., 1998a; Millan et al., 1999), but not
for ketamine. Likewise, previous work had shown
increases in 5-hydroxyindoleacetic acid (5-HIAA) fol-
lowing MK-801 administration (Kashiwa et al., 1995;
Lindefors et al., 1997 ; Lo¨scher et al., 1993), which
could be indicative of an enhanced 5-HT metabolism
and/or release. Altogether these ﬁndings indicate that
an increased serotonergic transmission in the mPFC is
a general response to NMDA receptor hypofunction.
There does not seem to be diﬀerences between com-
petitive and non-competitive NMDA receptor an-
tagonists since both classes of compounds produce a
similar activation of cortical serotonergic pathways
(Lo¨scher et al., 1993) and 5-HT release (Ceglia et al.,
2004). Furthermore, this eﬀect does not result from a
direct action of these compounds on the mPFC be-
cause the local application of PCP or ketamine did not
produce any change in the concentration of 5-HT.
In line with our results, the intra-mPFC administration
of NMDA receptor antagonists does not aﬀect the local
neuronal activity (Aghajanian and Marek, 2000; Jodo
et al., 2003 ; Suzuki et al., 2002), which suggests that
the NMDA receptors responsible for such actions are
located outside the mPFC. One possible site of action
of NMDA receptor antagonists is the ventral hippo-
campus because the local application of PCP or
MK-801 in this region increases the ﬁring of pyramidal
neurons in the mPFC (Jodo et al., 2005). According to
the hypothesis of the disinhibition of glutamatergic
input to the mPFC (see Introduction), PCP and keta-
mine would increase glutamate release onto
non-NMDA receptors in the mPFC (Krystal et al.,
2003 ; Lorrain et al., 2003 ; Moghaddam et al., 1997).
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Figure 2. Eﬀects of phencyclidine (PCP) 5 mg/kg i.p. on the
5–HT eﬄux in the mPFC alone (n=8) or in combination with
antipsychotic drugs (a) or receptor antagonists (b). Data
(mean¡S.E.M.) in (a) and (b) are expressed as percentage of
baseline. The group SAL+PCP in (a) has been replotted in
(b). Data in (c) represent the area under the curve (AUC) of
the diﬀerent treatments. PCP increased dialysate 5-HT with
respect to the control group (n=6) that received two
injections of saline (SAL). The eﬀect of PCP was blocked by
pretreatment with clozapine 1.0 mg/kg s.c. (CLZ, n=5),
olanzapine 1.0 mg/kg s.c. (OLZ, n=8) and prazosin 0.3 mg/
kg, s.c. (PRZ, n=4), but not by haloperidol 0.1 mg/kg s.c.
(HAL 0.1, n=4), haloperidol 1.0 mg/kg s.c. (HAL 1, n=5) or
ritanserin 5.0 mg/kg i.p. (RIT, n=5). * p<0.05 compared to
SAL+PCP group and # p<0.05 compared to SAL+SAL
group.
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The stimulation of such non-NMDA receptors would,
in turn, produce an enhanced glutamatergic output
from the mPFC neurons, including those projecting to
the dorsal raphe nucleus, thereby enhancing sero-
tonergic cell ﬁring and cortical 5-HT eﬄux. Therefore,
the observed eﬀects on 5-HT eﬄux would be second-
ary to a primary release of glutamate in the mPFC. In
line with these results, the release of 5-HT in the mPFC
evoked by the 5-HT2A/2C receptor agonist 1-(2,5-di-
methoxy-4-iodophenyl)-2-aminopropane (DOI) or the
a1-adrenoceptor agonist cirazoline was reversed by
the a-amino-3-hydroxy-5-methyl-4-isoxazole propi-
onate (AMPA)/kainate receptor blockade and by the
activation of mGluR2/3 receptors (Amargo´s-Bosch et
al., 2003 ; Bortolozzi et al., 2003 ; Martı´n-Ruiz et al.,
2001). However, although this functional interplay
between the mPFC and the dorsal raphe nucleus is
well documented (Amargo´s-Bosch et al., 2003; Celada
et al., 2001; Hajo´s et al., 1998 ; Lucas et al., 2005 ;
Martı´n-Ruiz et al., 2001), a direct inﬂuence of NMDA
receptor antagonists on serotonergic neurons at the
level of the dorsal raphe nucleus cannot be discarded.
Indeed, the local application of MK-801 into the dorsal
raphe nucleus increases the local release of 5-HT both
in vitro (Callado et al., 2000) and in vivo (Tao and
Auerbach, 2000). A third alternative could be that the
NMDA receptor antagonist-induced excess of cortical
glutamate would act on AMPA receptors presumably
located on serotonergic terminals in the mPFC, thus
promoting 5-HT release. Several reports have de-
scribed the presence of such AMPA receptors in the
presynaptic compartment with a role in the regulation
of transmitter release (Schenk and Matteoli, 2004).
Moreover, the existence of presynaptic AMPA
receptors in serotonergic nerve endings has been
proposed in other regions of the brain (Maione et al.,
1997) although it remains to be determined in the
mPFC.
The second important ﬁnding of the present study
is that the increased eﬄux of 5-HT produced by the
systemic administration of PCP and ketamine was
reversed by the atypical antipsychotics clozapine and
olanzapine, but not by the classical antipsychotic
haloperidol. The blocking eﬀect of olanzapine was
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Figure 3. Eﬀects of ketamine (KET) 25 mg/kg s.c. on the 5-HT
eﬄux in the mPFC alone (n=9) or in combination with
antipsychotic drugs (a) or receptor antagonists (b). Data
(mean¡S.E.M.) in (a) and (b) are expressed as percentage of
baseline. The group SAL+KET in (a) has been replotted in
(b). Data in (c) represent the area under the curve (AUC) of
the diﬀerent treatments. Ketamine increased dialysate 5-HT
with respect to the control group (n=5) that received two
injections of saline (SAL). The eﬀect of ketamine was blocked
by pretreatment with clozapine 1.0 mg/kg s.c. (CLZ, n=5),
olanzapine 1.0 mg/kg s.c. (OLZ, n=7) and prazosin 0.3 mg/
kg s.c. (PRZ, n=5), but not by haloperidol 1.0 mg/kg s.c.
(HAL 1, n=4) or ritanserin 5.0 mg/kg i.p. (RIT, n=4).
* p<0.05 compared to SAL+KET group and # p<0.05
compared to SAL+SAL group.
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delayed in comparison with that of clozapine, which
may be related to diﬀerences in kinetics of the drugs.
In general, atypical antipsychotics have been shown to
be more eﬀective than classical antipsychotics in re-
versing behavioural deﬁcits (for review, see Jentsch
and Roth, 1999) and the blockade of NMDA responses
on pyramidal neurons of the mPFC (Wang and Liang,
1998) elicited by PCP. It remains to be determined,
however, if the eﬀects of clozapine and olanzapine are
dependent on cortical glutamate changes. Previous
research appeared to point in that direction inasmuch
as clozapine tended to block glutamate eﬄux induced
by PCP (Adams and Moghaddam, 2001). However,
the high variability of the responses precluded any
deﬁnitive conclusion. On the other hand, the eﬀects of
PCP and ketamine were antagonized by the selective
a1-adrenoceptor antagonist prazosin. Both clozapine
and haloperidol possess a similar aﬃnity for the
a1-adrenoceptor (Arnt and Skarsfeldt, 1998 ; Millan
et al., 1998) and together with olanzapine are able to
inhibit serotonergic cell ﬁring in the dorsal raphe
nucleus through a1-adrenoceptor antagonism (Millan
et al., 1998 ; Sprouse et al., 1999). Furthermore, cloza-
pine and haloperidol occupy a similar amount (y50%)
of cortical a1-adrenoceptors at the doses used in the
present work (Chaki et al., 1999). Altogether these
ﬁndings would suggest that, at the doses tested, the
partial occupancy of a1-adrenoceptors is not respon-
sible for the diﬀerent eﬀects of these drugs on the
eﬄux of 5-HT and that these eﬀects would not result
from an inhibition of serotonergic cell ﬁring but rather
from a direct cortical action. In contrast, the dose of
prazosin fully occupies brain a1-adrenoceptors (Patel
et al., 2001). Thus, its eﬀects may result not only from a
post-synaptic action in the mPFC since its local appli-
cation in the mPFC markedly reduced 5-HT release
(Amargo´s-Bosch et al., 2003), but also from its strong
inhibition of serotonergic cell ﬁring at the raphe level
(Baraban and Aghajanian, 1980). Nevertheless, it
should be kept in mind that the sole blockade of
a1-adrenoceptors does not posses antipsychotic action.
In addition to a1-adrenoceptors, clozapine and
olanzapine exhibit aﬃnities much greater than that of
haloperidol for 5-HT2C receptors (Arnt and Skarsfeldt,
1998 ; Bymaster et al., 1996). However, antagonism at
5-HT2C receptors increases serotonergic transmission.
Thus, a selective 5-HT2C receptor antagonist (SB
242084) is able to potentiate cortical 5-HT release eli-
cited by 5-HT reuptake blockade (Cremers et al., 2004).
This is probably the mechanism by which ritanserin
slightly but signiﬁcantly increased mPFC 5-HT in the
present work.
Finally, clozapine and olanzapine share a high
aﬃnity for the 5-HT2A receptor (Arnt and Skarsfeldt,
1998 ; Bymaster et al., 1996), which suggests that this
receptor could theoretically play a role in the action of
these drugs in reducing the increased eﬄux of 5-HT
evoked by PCP and ketamine. In fact, the 5-HT2A/2C
receptor antagonist ritanserin was able to abolish
the eﬀects of PCP on the 5-HT eﬄux, which can be
predominantly attributed to its 5-HT2A antagonistic
properties (see above). In accord with our results, the
selective 5-HT2A receptor antagonist, M100907, oﬀsets
the PCP-induced hyperlocomotion, although PCP
does not directly interact with 5-HT2A receptors
(Millan et al., 1999). In addition, the pharmacological
stimulation of the mPFC with S-AMPA is also
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of baseline. Data in (b) represent the area under the curve
(AUC) of the diﬀerent treatments. With respect to the saline-
treated group (SAL, n=7), only haloperidol (* p<0.05),
clozapine (* p<0.02) and prazosin (* p<0.005) signiﬁcantly
reduced 5-HT eﬄux.
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reversed by 5-HT2A receptor antagonists (Amargo´s-
Bosch et al., 2003), which suggests that the 5-HT2A
antagonism is able to counteract an excessive stimu-
lation of AMPA receptors in the mPFC. However,
ritanserin did not antagonize the ketamine-induced
increase in 5-HT eﬄux, despite it being somewhat
lower than that produced by PCP. One possibility of
reconciling these apparently discordant ﬁndings is
that 5-HT2A/2C receptor blockade may be eﬀective only
in conditions of a high serotonergic tone. In accord-
ance with this, M100907 can block MK-801-induced
hyperlocomotion, but not after 5-HT depletion (Martin
et al., 1998b). The precise location of the 5-HT2A
receptors responsible for these eﬀects remains to be
determined. It is of signiﬁcance that, although
M100907 is able to block the eﬀects of 5-HT2A receptor
agonists at the level of the dorsal raphe nucleus
(Boothman et al., 2003), the evidence that 5-HT cells
do not express 5-HT2A receptors (Cornea-He´bert et al.,
1999 ; Pompeiano et al., 1994) further suggests that
post-synaptic (possibly cortical) 5-HT2A receptors are
involved.
Regardless of the precise mechanism, it seems that
the ability to prevent the NMDA receptor antagonist-
induced enhancement of 5-HT eﬄux in the mPFCmay
be a characteristic of atypical antipsychotic drugs. At
the dose of 1 mg/kg, it is possible that occupancy of
both a1-adrenergic and 5-HT2A receptors by clozapine
and olanzapine may contribute to the blockade of the
NMDA receptor antagonism-induced increase in cor-
tical 5-HT eﬄux. Given that an overactive serotonergic
transmission has been inferred to occur in schizo-
phrenia, a reduction of 5-HT in the mPFC may be
suggestive of a better antipsychotic proﬁle for
negative-cognitive symptoms. It must be taken into
consideration, however, that the eﬀects observed in
the present work are limited to the pharmacological
proﬁles of clozapine and olanzapine. While all classi-
cal antipsychotics are characterized by a predominant
D2 receptor antagonism, within the atypical class each
drug possesses a distinct pharmacological proﬁle. It is,
therefore, diﬃcult to assign the blockade of NMDA
receptor antagonist-induced release of cortical 5-HT
to a particular receptor interaction, although the
5-HT2A receptor seems to have an important
contribution.
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